AADI vs. VTYX, ELDN, PBYI, NMRA, INMB, DMAC, FATE, ALTS, ACTU, and ENGN
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Ventyx Biosciences (VTYX), Eledon Pharmaceuticals (ELDN), Puma Biotechnology (PBYI), Neumora Therapeutics (NMRA), INmune Bio (INMB), DiaMedica Therapeutics (DMAC), Fate Therapeutics (FATE), Janone (ALTS), Actuate Therapeutics (ACTU), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs. Its Competitors
Ventyx Biosciences (NASDAQ:VTYX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, community ranking, risk and analyst recommendations.
Aadi Bioscience has higher revenue and earnings than Ventyx Biosciences. Ventyx Biosciences is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ventyx Biosciences had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for Ventyx Biosciences and 0 mentions for Aadi Bioscience. Ventyx Biosciences' average media sentiment score of 0.87 beat Aadi Bioscience's score of 0.00 indicating that Ventyx Biosciences is being referred to more favorably in the media.
Ventyx Biosciences received 20 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 46.97% of users gave Ventyx Biosciences an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
Ventyx Biosciences has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Ventyx Biosciences' return on equity of -54.94% beat Aadi Bioscience's return on equity.
Ventyx Biosciences has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.
Ventyx Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 290.63%. Aadi Bioscience has a consensus target price of $1.67, indicating a potential downside of 18.30%. Given Ventyx Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Ventyx Biosciences is more favorable than Aadi Bioscience.
97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 14.5% of Ventyx Biosciences shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Ventyx Biosciences beats Aadi Bioscience on 13 of the 17 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy AADI Stock Free AADI Stock Alerts